Global Demographic Trends Will Spur Clinical Advances

Published
17 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$7.44
6.1% overvalued intrinsic discount
15 Aug
US$7.89
Loading
1Y
-64.8%
7D
7.9%

Author's Valuation

US$7.4

6.1% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 Aug 25
Fair value Increased 12%

Fortrea Holdings’ price target has been revised upward to $7.02, primarily due to solid earnings visibility and positive physician survey results for hospital segments, despite cost challenges in managed care and a neutral outlook in clinical laboratories. Analyst Commentary Earnings visibility remains solid for hospital-focused segments.